Comprehensive analysis of an ATF/CREB family-based signature with regard to prognosis and immune feature in adrenocortical carcinoma

Yige Jia,Kan Wu,Xiang Li,Yuchun Zhu,Zhihong Liu
DOI: https://doi.org/10.21203/rs.3.rs-4278365/v1
2024-01-01
Abstract:Abstract Background The ATF/CREB family members play important roles in tumourigenesis and immunity across various cancers. However, the expression patterns and clinical significance of ATF/CREB family members in adrenocortical carcinoma (ACC) remain unrevealed. This study aimed to investigate the gene expression profiles of ATF/CREB family members in ACC and develop a prognostic signature based on this family. Methods Utilizing data from The Cancer Genome Atlas (TCGA), we evaluated the expression levels of 21 ATF/CREB genes in ACC. A prognostic model was constructed using Lasso and Cox regression analyses, with the TCGA cohort as the training dataset, and further validated using an independent Gene Expression Omnibus (GEO) dataset and ATF4 immunohistochemical data from 78 samples. Kaplan-Meier and multivariable Cox analyses were performed to validate the accuracy of the prognostic model. Additionally, the relationship between the prognostic signature, immune checkpoints, and immune cell populations was examined. Results Our findings revealed that the ATF/CREB family-based signature significantly stratified ACC cases into high- and low-risk groups based on overall survival (OS) in the TCGA dataset. Furthermore, the signature remained an independent prognostic factor in multivariate analyses and its clinical significance was well validated in different clinical subgroups and independent validation cohorts. Notably, high-risk signature patients exhibited distinct immune cell proportions and immune-suppressive states. Additionally, the signature scores were negatively associated with multiple immunotherapy biomarkers. Conclusions This study presents the first ATF/CREB family-based model for predicting survival outcomes and immune landscapes for ACC patients. The prediction capability of this signature for predicting prognosis and immunotherapy response warrants further validation.
What problem does this paper attempt to address?